Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

May 14, 2024

https://www.globenewswire.com/news-release/2024/05/14/2881500/0/en/Celularity-Data-Published-in-Journal-for-ImmunoTherapy-of-Cancer-Reveals-Benefits-of-Placental-Circulating-T-Cells-for-CAR-T-Therapy.html

FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ:CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of Cancer, published data highlighting the potential advantages of Celularity’s T-Cell platform for future immunotherapies including chimeric antigen receptor (CAR-T) therapies.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.